Kevin McGurk

Dr. Kevin McGurk

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2020 in JACEP Open
Verified
Journal Article
Open access
PDF file
KMKevin McGurk
Kevin McGurk
TRToni Riveros
Toni Riveros
NJNicholas Johnson
Nicholas Johnson
SDSean Dyer
Sean Dyer
Historically, the prone position was used almost exclusively in the ICU for patients suffering from refractory hypoxemia due to acute respiratory distress syndrome (ARDS). Amidst the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic, however, this technique has been increasingly utilized in settings outside of the ICU, particularly in the emergency department. With emerging evidence that patients diagnosed with COVID‐19 who are not intubated and mechanically ventilated may benefit from the prone position, this strategy should not be isolated to only those with critical illness. This is a review of the pertinent physiology and evidence supporting prone positioning along with a step‐by‐step guide meant to familiarize those who are not already comfortable with the maneuver. Placing a patient in the prone position helps to improve ventilation‐perfusion matching, dorsal lung recruitment, and ultimately gas exchange. Evidence also suggests there is improved oxygenation in both mechanically ventilated patients and those who are awake and spontaneously breathing, further reinforcing the utility of the prone position in non‐ICU settings. Given present concerns about resource limitations because of the pandemic, prone positioning has especially demonstrable value as a technique to delay or even prevent intubation. Patients who are able to self‐prone should be directed into the ''swimmer's position'' and then placed in reverse Trendelenburg position if further oxygenation is needed. If a mechanically ventilated patient is to be placed in the prone position, specific precautions should be taken to ensure the patient's safety and to prevent any unwanted sequelae of prone positioning.

11 December 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
SFSadia Farzana
Sadia Farzana
FRFrancesco Maria Rossi
Francesco Maria Rossi
KAKatie S. Allen
Katie S. Allen
QLQian Luo
Qian Luo
JWJeff Whittle
Jeff Whittle
BBBernard S. Black
Bernard S. Black
Objective: This study aimed to assess COVID-19 vaccine effectiveness against death (VE), controlling for healthy vaccinee bias. Methods: We link all adult deaths through year-end 2022 in the State of Indiana, U.S.A., to vaccination records and identify which deceased received primary vaccination (measured as either one or two initial doses) and which received one or two booster doses. We measure COVID-19 mortality with the COVID Excess Mortality Percentage (CEMP). CEMP is calculated, for a group defined by various characteristics (age, sex, time period), as COVID-19 deaths divided by non-COVID natural deaths. The CEMP outcome measure accounts for healthy vaccinee bias by using non-COVID natural mortality to control for differences in population health. Results: We find a large healthy vaccinee bias. Controlling for this bias, we find substantial VE for primary vaccination and the first booster dose during the first five vaccine-available calendar quarters, from 1Q2021 through 1Q2022 (end of Omicron infection wave). However, over 2Q–4Q2022, we find no evidence for primary-vaccination VE, and find moderate but statistically insignificant booster VE, which largely wanes by 4Q2022. Conclusions: It is known that by 2Q2022, most people had natural immunity from prior COVID-19 infection. Thus, our results for 2Q–4Q2022 largely reflect comparing hybrid (infection plus vaccination) immunity to infection-only immunity. In this period, we find negligible mortality benefit from primary vaccination, and moderate but waning benefit from a booster dose. Policy Implications: Controlling for healthy vaccinee bias is crucial when estimating VE. We found limited VE against COVID-19 mortality over 2Q–4Q2022, but lacked data for more recent periods.

1 April 2020 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
JKJuleigh Nowinski Konchak
Juleigh Nowinski Konchak
KMKevin McGurk
Kevin McGurk
KHKeiki Hinami
Keiki Hinami
MVMargaret Vacchiano
Margaret Vacchiano
SASteven Aks
Steven Aks

3 April 2023 in The Journal of Emergency Medicine
Verified
Journal Article
Closed access
KMKevin McGurk
Kevin McGurk
AHAsma Hashim
Asma Hashim
CBCarisa Bergner
Carisa Bergner
MSMichael Schindlbeck
Michael Schindlbeck
SDSean Dyer
Sean Dyer

4 October 2025 in Western Journal of Emergency Medicine
Verified
Journal Article
Open access
PDF file
PTParnika Telagi
Parnika Telagi
RSRichard Sadler
Richard Sadler
PTPraval Telagi
Praval Telagi
KMKevin McGurk
Kevin McGurk
Introduction: Urgent care centers (UC) play an important role in addressing non-emergent health concerns, offering a convenient alternative to emergency departments (ED). However, accessibility to UCs can vary based on transportation availability and socioeconomic factors. In this study we evaluated the geospatial accessibility of UCs and EDs in Milwaukee County, Wisconsin, and sought to characterize the relationship between transit options, socioeconomic vulnerability, and access to care. Methods: We included 13 EDs and 13 UCs in the study. Public and private transit times between census tracts in Milwaukee County and the nearest UC or ED were calculated using an application programming interface that recorded data from Google Maps. We employed socioeconomic vulnerability index (SEVI) scores to define community vulnerability. Statistical analyses, including Mann-Whitney U tests and Pearson correlation coefficients, were used to determine differences in commute times and their relationship with socioeconomic status. Results: Private transit times were shorter than public transit times when commuting to the nearest ED (7 minutes vs 22 minutes, P <.001) and the nearest UC (9 minutes vs 31 minutes, P < .001). The EDs were generally more accessible than UCs, with shorter transit (22 vs 31 minutes, P < .001) and walk times (11 vs 14 minutes, P <.001). Socioeconomically disadvantaged communities with higher SEVI scores had longer private transit times to UCs (r = 0.17, P = .003) while having shorter public transit times to EDs (r = -.21, P < .001). Conclusion: Access to urgent care centers and EDs in Milwaukee County is influencedby socioeconomic factors and transportation modes. While EDs are more accessible to socioeconomically vulnerable communities, UCs are less accessible, which may contribute to higher ED utilization for non-emergent needs. These findings highlight the need to address transportation limitations as a social determinant of health that can impact how disadvantaged populations seek care and the implications for non-emergent ED use and ED crowding.

20 August 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
SFSadia Farzana
Sadia Farzana
FRFrancesco Maria Rossi
Francesco Maria Rossi
QLQian Eric Luo
Qian Eric Luo
JWJeff Whittle
Jeff Whittle
KMKevin McGurk
Kevin McGurk
BBBernard S. Black
Bernard S. Black
Objective: It is commonly believed in the public health community that the mRNA vaccines from Pfizer and Moderna were broadly similar in preventing COVID-19 mortality, with perhaps a small advantage for Moderna. We revisit this question, using a research design that controls for healthy-vaccinee bias. Methods: We studied deaths among persons aged 15 years or greater from January 2021 through December 2022 in Indiana, linked to vaccination records, using an outcome measure, namely COVID-19 Excess Mortality Percentage (CEMP), which uses non-COVID natural mortality to control for HVB. Results: We find both large healthy-vaccinee bias for both vaccines, and larger bias for Pfizervaccinees: Pfizer recipients were healthier and thus would have faced lower COVID-19 mortality without vaccination. For ages 60+, we find almost 50% higher COVID-19 remaining mortality risk (RMR) for Pfizer vaccinees receiving primary vaccination over a “core period” from 2Q2021 through 1Q2022: the average Pfizer/Moderna RMR ratio was 1.49. For ages 15–59, this ratio was 1.25, but was not statistically significant. For booster dose for ages 60+, the average Pfizer/Moderna RMR ratio was 1.34. For 2Q2022 through 4Q2022, after the major Omicron wave, we find much lower vaccine effectiveness and no significant Pfizer–Moderna difference. Conclusions: During the period with both good vaccine availability and high COVID-19 mortality (2Q-2021–1Q2022), the Moderna vaccine was associated with lower COVID-19 mortality, relative to the Pfizer vaccine. A possible explanation is the higher Moderna dose (100 μg vs. 30 for Pfizer). After that period, a high percentage of the population had natural immunity from prior COVID-19 infection; we find only small mortality gains from vaccination, with no significant Pfizer–Moderna difference. Policy Implications: Controlling for healthy-vaccinee bias, Moderna was associated with lower COVID-19 mortality, relative to Pfizer. This difference was not known in real-time due to the failure of the available studies to address healthy-vaccinee bias. Controlling for such bias is vital when making vaccination policy.